Relay Therapeutics RLAY 深 滬
已收盤 09-19 16:00:00 美东时间
7.86
+0.280
+3.69%
華盛通- 最 高8.04
- 今 開7.87
- 成交量 148.19万股
- 最 低 7.6901
- 昨 收 7.58
- 總市值 12.77亿
- 52周最高 12.14
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 5.70
- 委 比 92.41%
- 總股本 1.62亿
- 歷史最高 64.37
- 量 比 0.52
- 振 幅 4.62%
- 歷史最低 5.70
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Relay up 5% as Street applauds breast cancer candidate data
Relay Therapeutics (NASDAQ:RLAY) is up ~5% in premarket trading after Stifel and HC Wainwright issued bullish notes on the stock following promising interim data on a breast cancer asset. Those result...
09-16 20:22
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.
09-12 00:22
Relay Therapeutics prices $200M stock offering
Clinical-stage precision medicine company Relay Therapeutics (NASDAQ:RLAY) priced an underwritten public offering of ~28.57M shares at $7.00 per share. Underwriters have a 30-day option to purchase up...
09-11 14:31
Reported Earlier, Relay Therapeutics Prices $200M Public Offering Of 28,571,429 Common Shares At $7/Share
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $200 million, excluding any exercise of the
09-11 14:26
快讯 | Relay Therapeutics宣布普通股公开发行定价
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
09-11 08:21
Relay upgraded by Jefferies, downgraded by Oppenheimer
Relay Therapeutics (NASDAQ:RLAY) was upgraded by Jefferies but downgraded by Oppenheimer on Tuesday, the day after the shares rallied over 50% on positive data for its breast cancer drug candidate RLY...
09-11 04:35
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns about competitor data and efficacy challenges.
09-11 02:50
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-10 22:03
Jefferies Upgrades Relay Therapeutics to Buy, Raises Price Target to $16
Jefferies analyst Akash Tewari upgrades Relay Therapeutics (NASDAQ:RLAY) from Hold to Buy and raises the price target from $10.6 to $16.
09-10 20:28
Oppenheimer Downgrades Relay Therapeutics to Perform
Oppenheimer analyst Matthew Biegler downgrades Relay Therapeutics (NASDAQ:RLAY) from Outperform to Perform.
09-10 18:48
